These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20526296)

  • 1. Cancer vaccine approval could open floodgates.
    Nat Med; 2010 Jun; 16(6):615. PubMed ID: 20526296
    [No Abstract]   [Full Text] [Related]  

  • 2. A prostate cancer 'vaccine' under development.
    Mayo Clin Health Lett; 2009 Dec; 27(12):4. PubMed ID: 20082492
    [No Abstract]   [Full Text] [Related]  

  • 3. Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product.
    Baghdadi R
    Oncology (Williston Park); 2010 Sep; 24(10):881-3. PubMed ID: 21138168
    [No Abstract]   [Full Text] [Related]  

  • 4. Cellular immunotherapy licensed for advanced prostate cancer.
    Traynor K
    Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
    [No Abstract]   [Full Text] [Related]  

  • 5. Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
    Chambers JD; Neumann PJ
    N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004
    [No Abstract]   [Full Text] [Related]  

  • 6. Abigail Alliance v. Von Eschenbach: restricting access to potentially lifesaving drugs singe 2007.
    Goodman AJ
    J Contemp Health Law Policy; 2008; 25(1):107-41. PubMed ID: 19137749
    [No Abstract]   [Full Text] [Related]  

  • 7. The regulator disapproves.
    Nat Biotechnol; 2008 Jan; 26(1):1. PubMed ID: 18182998
    [No Abstract]   [Full Text] [Related]  

  • 8. Fallout from flip-flops.
    Froese P
    Nat Biotechnol; 2008 Jun; 26(6):614-5. PubMed ID: 18536677
    [No Abstract]   [Full Text] [Related]  

  • 9. The Provenge decision.
    DeVita VT
    Nat Clin Pract Oncol; 2007 Jul; 4(7):381. PubMed ID: 17554239
    [No Abstract]   [Full Text] [Related]  

  • 10. Death threats for discrepancies over treatment data.
    Burton A
    Lancet Oncol; 2007 Jul; 8(7):577. PubMed ID: 17668482
    [No Abstract]   [Full Text] [Related]  

  • 11. Consultation corner. Prostate cancer vaccine offers new direction.
    Drake C
    Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):6-7. PubMed ID: 20848753
    [No Abstract]   [Full Text] [Related]  

  • 12. Putting Provenge in perspective.
    Moul JW
    Oncology (Williston Park); 2011 Mar; 25(3):255, 258. PubMed ID: 21548468
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy: a new option for advanced prostate cancer.
    Harv Mens Health Watch; 2010 Sep; 15(2):1-2. PubMed ID: 20941869
    [No Abstract]   [Full Text] [Related]  

  • 14. Concerns about Provenge simmer as CMS ponders coverage.
    Goozner M
    J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996
    [No Abstract]   [Full Text] [Related]  

  • 15. New therapies for castration-resistant prostate cancer.
    Longo DL
    N Engl J Med; 2010 Jul; 363(5):479-81. PubMed ID: 20818868
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment.
    Drake C
    Urology; 2013 Jun; 81(6):1302. PubMed ID: 23582480
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic cancer vaccine survives biotech bust.
    Ledford H
    Nature; 2015 Mar; 519(7541):17-8. PubMed ID: 25739610
    [No Abstract]   [Full Text] [Related]  

  • 18. Lower baseline PSA predicts greater benefit from sipuleucel-T.
    Petrylak D
    Clin Adv Hematol Oncol; 2013 Jun; 11(6):377-81. PubMed ID: 24472808
    [No Abstract]   [Full Text] [Related]  

  • 19. The landmark approval of Provenge, what it means to immunology and "in this issue": the complex relation between vaccines and autoimmunity.
    Bot A
    Int Rev Immunol; 2010 Jun; 29(3):235-8. PubMed ID: 20521923
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate cancer.
    Brody H
    Nature; 2015 Dec; 528(7582):S117. PubMed ID: 26672779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.